Sung J Choi Yoo1, John A Nyman1, Andrea L Cheville2, Kurt Kroenke3. 1. Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN. 2. Department of Physical Medicine and Rehabilitation, Mayo Clinic. 3. VA HSR&D Center for Health Information and Communication, Regenstrief Institute, Inc., and Indiana University School of Medicine. Electronic address: kkroenke@regenstrief.org.
Abstract
OBJECTIVE:Pain and depression are prevalent and treatable symptoms among patients with cancer, yet they are often undetected and undertreated. The Indiana Cancer Pain and Depression (INCPAD) trial demonstrated that telecare management can improve pain and depression outcomes. This article investigates the incremental cost effectiveness of the INCPAD intervention. METHODS: The INCPAD trial was conducted in 16 community-based urban and rural oncology practices in Indiana. Of the 405 participants, 202 were randomized to the intervention group and 203 to the usual-care group. Intervention costs were determined, and effectiveness outcomes were depression-free days and quality-adjusted life years. RESULTS: The intervention group was associated with a yearly increase of 60.3 depression-free days (S.E. = 15.4; P < 0.01) and an increase of between 0.033 and 0.066 quality-adjusted life years compared to the usual care group. Total cost of the intervention per patient was US$1189, which included physician, nurse care manager and automated monitoring set-up and maintenance costs. Incremental cost per depression-free day was US$19.72, which yields a range of US$18,018 to US$36,035 per quality-adjusted life year when converted to that metric. When measured directly, the incremental cost per quality-adjusted life year ranged from US$10,826 based on the modified EQ-5D to US$73,286.92 based on the SF-12. CONCLUSION: Centralized telecare management, coupled with automated symptom monitoring, appears to be a cost effective intervention for managing pain and depression in cancer patients. Published by Elsevier Inc.
RCT Entities:
OBJECTIVE:Pain and depression are prevalent and treatable symptoms among patients with cancer, yet they are often undetected and undertreated. The Indiana Cancer Pain and Depression (INCPAD) trial demonstrated that telecare management can improve pain and depression outcomes. This article investigates the incremental cost effectiveness of the INCPAD intervention. METHODS: The INCPAD trial was conducted in 16 community-based urban and rural oncology practices in Indiana. Of the 405 participants, 202 were randomized to the intervention group and 203 to the usual-care group. Intervention costs were determined, and effectiveness outcomes were depression-free days and quality-adjusted life years. RESULTS: The intervention group was associated with a yearly increase of 60.3 depression-free days (S.E. = 15.4; P < 0.01) and an increase of between 0.033 and 0.066 quality-adjusted life years compared to the usual care group. Total cost of the intervention per patient was US$1189, which included physician, nurse care manager and automated monitoring set-up and maintenance costs. Incremental cost per depression-free day was US$19.72, which yields a range of US$18,018 to US$36,035 per quality-adjusted life year when converted to that metric. When measured directly, the incremental cost per quality-adjusted life year ranged from US$10,826 based on the modified EQ-5D to US$73,286.92 based on the SF-12. CONCLUSION: Centralized telecare management, coupled with automated symptom monitoring, appears to be a cost effective intervention for managing pain and depression in cancerpatients. Published by Elsevier Inc.
Authors: M Von Korff; W Katon; T Bush; E H Lin; G E Simon; K Saunders; E Ludman; E Walker; J Unutzer Journal: Psychosom Med Date: 1998 Mar-Apr Impact factor: 4.312
Authors: Paula Sherwood; Barbara A Given; Charles W Given; Victoria L Champion; Ardith Z Doorenbos; Faouzi Azzouz; Sharon Kozachik; Kim Wagler-Ziner; Patrick O Monahan Journal: Oncol Nurs Forum Date: 2005-11-03 Impact factor: 2.172
Authors: Wayne J Katon; Michael Schoenbaum; Ming-Yu Fan; Christopher M Callahan; John Williams; Enid Hunkeler; Linda Harpole; Xiao-Hua Andrew Zhou; Christopher Langston; Jürgen Unützer Journal: Arch Gen Psychiatry Date: 2005-12
Authors: Andrea M Barsevick; Kyra Whitmer; Lillian M Nail; Susan L Beck; William N Dudley Journal: J Pain Symptom Manage Date: 2006-01 Impact factor: 3.612
Authors: Jaya S Khushalani; Jin Qin; John Cyrus; Natasha Buchanan Lunsford; Sun Hee Rim; Xuesong Han; K Robin Yabroff; Donatus U Ekwueme Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2018-06-20 Impact factor: 2.217
Authors: Femke Jansen; Valesca van Zwieten; Veerle M H Coupé; C René Leemans; Irma M Verdonck-de Leeuw Journal: Asia Pac J Oncol Nurs Date: 2016 Apr-Jun